Gout is the most common form of inflammatory arthritis, with a worldwide prevalence of approximately 4%. The accumulation of ...
When you think of arthritis, achy, warm, swollen joints probably come to mind. These are indeed some of the most common symptoms of arthritis. But did you know there are actually over 100 different ...
Gout flare in the hand of an elderly person Researchers evaluated the efficacy and safety of anakinra for the treatment of acute gout flares. Undergoing 5 days of therapy with the IL-1 receptor ...
Morning Overview on MSN
CRISPR revives ancient gene to block gout and fatty liver
Reviving an ancient human gene that prevents gout and fatty liver disease, scientists at Georgia State University have marked a potential breakthrough in treating these metabolic conditions. Using ...
Xanthine oxidase inhibitors, primarily allopurinol and febuxostat, are the mainstay of treatment. The goal of chronic gout management includes lowering serum urate levels to below 6 mg/dL. 5 Overall, ...
NEW YORK CITY — Urate, the culprit of gout, affects the vasculature in multiple ways that can raise cardiovascular risk (CV) in an individual with gout, and following guidelines for gout treatment, ...
Management of a patient allergic to allopurinol can be considered a therapeutic challenge. This article highlights the diversity of medications that can be used to manage hyperuricemia during this ...
Gout is a growing threat to the world population. Moreover, the prevalence of comorbidities is higher in gout patients. Study: Urate-Lowering Therapy Use among US Adults with Gout and the Relationship ...
TOKYO, Jul 14, 2025 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has launched "URECE" (brand name in China: "Youlesi", generic name: ...
MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress ...
Once-weekly tirzepatide is associated with clinically relevant reductions in SUA levels over 72 weeks, largely driven by substantial weight loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results